Prostatitis: Symptoms, the Four Types, and What Actually Treats It

The commonest form of prostatitis is the one with no bacteria in it. NIH category III — chronic prostatitis/chronic pelvic pain syndrome — affects 10% to 15% of the male population (Murphy, 2009) and is the commonest urological diagnosis in men under fifty (Graziani, 2023); acute bacterial prostatitis is only about 10% of all prostatitis cases (Coker, 2016). In categories I and II antibiotics are not optional. In category III they are the most argued-over drug in urology — and this page will show you the argument rather than the half of it that suits me.

I lead with that because of who ends up in my room in Chennai. In my clinic, I see this every week. Not men on day two of a fever, but men on month fourteen — carrying a folder of urine culture reports that all say “no growth”, with three courses of ciprofloxacin behind them.

The type most men actually have is the one the internet explains worst. Here is the working, including the parts that cut against me. One thing comes before all of it.

The most dangerous way to read a page like this one is to have genuine category I and talk yourself out of hospital because someone told you antibiotics are over-prescribed. They are over-prescribed — for category III. For the man with a fever of 39 and rigors they are what stops him becoming very sick. If that is you tonight, stop reading and go.

If you read nothing else, read those six and the red box above them.

Talk to Dr Shah Dupesh

Quick facts

• Prostatitis affects approximately 9.3% of men in their lifetime (Borgert, 2025); community estimates run 5% to 9% (Roberts, 2000), and CP/CPPS specifically has a mean prevalence of 8% to 8.2% (Graziani, 2023).
• Acute bacterial prostatitis is only about 10% of all prostatitis cases (Coker, 2016).
• CP/CPPS is commonest in men under 50 (Graziani, 2023) and accounts for nearly 2 million outpatient visits a year (Murphy, 2009).
• “Chronic” means pelvic pain for at least three months (Borgert, 2025), conventionally three of the previous six (Rees, 2015).
• Sexual dysfunction affects 62% of men with CP/CPPS — erectile dysfunction 29%, premature ejaculation 40% (Li, 2016).

What prostatitis actually is

The prostate is a walnut-sized gland just below the bladder, wrapped around the top of the urethra. Every drop of urine and every millilitre of semen passes through the middle of it. That is why one organ produces three whole families of symptoms: urinary, pelvic and ejaculatory.

Now the part nobody says out loud. “-itis” means inflammation. It does not mean infection. Prostatitis is defined as infection, inflammation or pain of the prostate gland (Borgert, 2025). When it is bacterial the organisms are gram-negative — E. coli, Klebsiella, Pseudomonas in 80% to 97% of acute cases (Borgert, 2025). E. coli and Klebsiella are bowel organisms, which is where the reassuring line “these are your own bacteria” comes from; that much is basic microbiology, not a finding in the papers I cite. Pseudomonas is the exception — it tends to get in after instrumentation, and catheters, cystoscopy and transrectal biopsy are all recognised routes (Coker, 2016). In category III there is often no identifiable cause at all: the aetiology is, in the words of the review I lean on most here, poorly understood (Murphy, 2009).

The four NIH categories — the table nobody publishes

The framework was set out in an NIH consensus definition and classification of prostatitis in JAMA in 1999 (Krieger, 1999), and it redefined prostatitis into four distinct entities (Murphy, 2009). Every urologist works from it; almost no patient page explains it.

Category	What it is, and what it feels like	Bacteria?	Antibiotics?	What actually treats it
I — Acute bacterial	Sudden infection, ~10% of all prostatitis (Coker, 2016): fever, chills, low blood pressure (Murphy, 2009), dysuria, frequency and urinary retention (Coker, 2016)	Yes — gram-negative: E. coli, Klebsiella, Pseudomonas, 80–97% (Borgert, 2025)	Yes — urgently. Two to four weeks (Borgert, 2025)	Antibiotics, plus draining the bladder if the gland is blocking flow (Murphy, 2009); hospital and IV treatment if systemically ill (Coker, 2016)
II — Chronic bacterial	Recurrent urine infections with the same organism or strain (Borgert, 2025; Murphy, 2009), with pelvic pain, urinary symptoms and ejaculatory pain (Murphy, 2009)	Yes — on localisation cultures, ~90% accurate (Murphy, 2009)	Yes — long course. Four weeks minimum, up to twelve (Lam, 2023)	Antibiotics that penetrate prostate tissue (Perletti, 2013); recurrence after oral therapy is common (Su, 2020)
III — CP/CPPS IIIA inflammatory · IIIB non-inflammatory	Pelvic pain for more than three of the previous six months, urinary symptoms and painful ejaculation, without documented urinary infections (Murphy, 2009). IIIA was 54% to 90% of the NIH cohort depending on the cut-point used (Schaeffer, 2002)	Usually not — only 8% of 488 category III men had at least one localising uropathogen (Schaeffer, 2002)	Contested. Placebo-controlled trials were negative (Alexander, 2004; Nickel, 2003); guidelines still list them among first-line options (Rees, 2015). The full argument is below	Phenotype-directed multimodal care — pelvic floor physical therapy, alpha-blockers, neuromodulators, anti-inflammatories, cognitive behavioural therapy (Polackwich, 2016), delivered multimodally and multidisciplinarily (Lai, 2025)
IV — Asymptomatic	Inflammation with no symptoms, found incidentally during infertility or prostate cancer assessment (Murphy, 2009)	More than you would expect — quantitative full-microflora semen analysis found significantly more organisms and more species than in controls, an abundant mixed population (Korrovits, 2006), alongside white cells and raised seminal interleukin-6 (Korrovits, 2006)	No	Usually nothing — the clinical significance is unknown and it is often left untreated (Murphy, 2009)

Why the category decides everything

Same organ, same word on the discharge summary, different treatments. Category III is highly prevalent with no one-size-fits-all therapy backed by level-one evidence (Polackwich, 2016), and in my clinic it is the overwhelming majority of men arriving already labelled “prostatitis” — my observation, not a figure from a paper.

That table is the whole article in miniature. If you can place yourself in one of those four rows, you already know more than most men who have been treated for this for years.

The rest of this page is mostly about row three, because that is where almost everybody actually is — and where the treatment most often goes wrong.

The symptoms, and which ones matter

What are the 5 warning signs of prostatitis?

1. Pain between the scrotum and the back passage — the perineum — and in the testicles. That pain sits at the centre of the disabling symptom array of chronic bacterial prostatitis (Perletti, 2013), and three months of pelvic pain is what defines category III (Borgert, 2025).
2. Burning or pain passing urine, with frequency and urgency, including at night (Perletti, 2013; Coker, 2016). In CP/CPPS these present as voiding or storage lower urinary tract symptoms (Rees, 2015). Burning on its own is not diagnostic, though. It is also the commonest presenting symptom of chlamydia and gonorrhoea, which is exactly why the tests further down matter.
3. Pain during or after ejaculation — ejaculatory pain runs through categories II and III (Murphy, 2009).
4. Trouble emptying the bladder. Dysuria, frequency and urinary retention are recognised features of acute bacterial prostatitis (Coker, 2016), and an inflamed gland may block flow outright, which is why draining the bladder is part of category I treatment (Murphy, 2009).
5. Fever, chills and feeling systemically unwell — with possible nausea, vomiting and malaise (Coker, 2016). Fever or chills point to acute bacterial prostatitis (Borgert, 2025). That is the red box at the top of this page, not a “book next week” symptom.

Men also describe pain in the lower back, groin, abdomen, penis or rectum, and sometimes cloudy urine or blood in the semen — my clinic list, not a figure from these papers. If a change in your ejaculate brought you here, read what semen colour actually means first.

Those five are what I actually ask about, in that order.

Only the fifth one is an emergency on its own. The other four are what a proper assessment sorts out.

Antibiotics in category III: the evidence conflicts, and here is both halves

The direct placebo-controlled trials are negative

In 196 men with long-standing CP/CPPS — a mean of 6.2 years of symptoms, most already substantially treated — six weeks of ciprofloxacin was tested against tamsulosin, both, or placebo. Scores fell modestly in every arm including placebo, and ciprofloxacin did not substantially reduce symptoms (Alexander, 2004). A Canadian multicentre trial of levofloxacin against placebo in 80 men found both groups improved, with no statistically or clinically significant difference (Nickel, 2003). Their limits belong in the same breath: Alexander tested only six weeks and its authors say men who had received less previous treatment might have responded differently (Alexander, 2004), and Nickel’s authors call theirs a pilot study of eighty men (Nickel, 2003).

Cochrane lands in between. The 2019 Cochrane review of 99 studies in 9,119 men set its threshold at a 25% fall in the NIH symptom index or a six-point reduction, whichever came first. Quinolones came in 2.43 points below placebo (95% CI −4.72 to −0.15) — statistically real, on low-quality evidence, and well short of that threshold. Cochrane’s own wording is that antibiotics “may reduce” symptoms, and its summary lists them among interventions that may produce a reduction without increased adverse events (Franco, 2019). I read a 2.43-point average as a change most men would not feel. That is my interpretation of the number, not a contradiction of the paper.

One major paper cuts hard the other way

A 2011 JAMA systematic review and network meta-analysis of 23 trials estimated that antibiotics reduce total symptom scores by 9.8 points against placebo (95% CI −15.1 to −4.6), and that combining an alpha-blocker with an antibiotic gives the greatest benefit of all, 13.8 points (95% CI −17.5 to −10.2). Both clear the six points that count as a real difference, and the paper concludes that alpha-blockers, antibiotics and combinations of them appear to achieve the greatest improvement in symptom scores compared with placebo (Anothaisintawee, 2011). You are entitled to see that, and no page arguing my side should bury it.

Why do they disagree? Those JAMA figures come from a longitudinal mixed regression model used to compare treatments indirectly, across trials never run head-to-head (Anothaisintawee, 2011). Alexander and Nickel put the actual drugs against an actual placebo in men who actually had category III, and found nothing. The same JAMA paper opens by saying the trial evidence here is conflicting and the options controversial, and flags publication bias among the smaller alpha-blocker studies it pooled (Anothaisintawee, 2011). Indirect comparisons flatter treatments; direct placebo comparisons do not. That is why I weight the direct trials — but weighting them differently is not pretending the other paper does not exist.

My most-cited source disagrees with me too. Murphy’s review, which I use throughout this page for the category framework, lists a four- to six-week fluoroquinolone as the first therapeutic measure in category III, reports that it provides relief in 50% of men and works better the sooner it is given, and sets out an algorithm in which the course may be repeated if the first gave relief (Murphy, 2009). I have leaned on that paper a dozen times here and I will not quietly skip the paragraph where it disagrees with me. My reading is that the 50% comes from uncontrolled series — Nickel’s report opens by noting exactly that, that uncontrolled studies had supported antibiotics in CP/CPPS, which is why he built a placebo arm (Nickel, 2003) — and that where a placebo arm exists, it moves about as far as the drug.

The guideline is more nuanced than I am. For a population that explicitly includes CP/CPPS, options for first-line treatment include antibiotics, alpha-adrenergic antagonists where voiding symptoms are present, and simple analgesics — and then, in the same paragraph, repeated use of antibiotics such as quinolones should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause (Rees, 2015). My position sits on the second half of that sentence, not the first.

Here’s the honest answer, stated as mine rather than as consensus. One adequate, time-limited course of an appropriate antibiotic is reasonable in a man who has never had one, and more than reasonable where an organism has actually been found or the picture looks like category II. What I cannot support is the third and fourth open-ended course in a man with no organism and no response to the first two — which is what most men in my clinic arrive having had. That is my clinical practice, not a trial result, and I would rather own the divergence from the guideline than dress it up as consensus.

How I am weighing all this, in both directions

The strongest evidence against antibiotics here is placebo-controlled. What I recommend instead rests on weaker evidence, and I will not pretend otherwise. That 8.8-point improvement from treating this as a psychoneuromuscular disorder? A before-and-after figure across 280 men in eight studies, with no placebo group (Anderson, 2018). Phenotype-directed care and its 75% to 84% improvement rate comes from three independent studies, not randomised trials (Polackwich, 2016). And the pelvic floor trial below is a feasibility study of 47 people. Some of those gains may be the same non-specific improvement the placebo arms showed. I recommend them anyway because they are low-harm, they target something I can demonstrate in the room, and the alternative on offer is a fourth course of antibiotics. That is a judgement call and you are entitled to see it as one.

Repeat courses are not harmless

Antimicrobial resistance is rising — it is why gonorrhoea has become hard to treat, and the same pressure limits options for men who genuinely need these drugs. It also contributes to recurrence in true chronic bacterial prostatitis (Lam, 2023; Su, 2020). Fluoroquinolones also carry prescribing-label warnings for tendon injury, nerve injury and, less commonly, aortic problems — regulatory labelling, not trial data from these papers, and I flag it as such.

None of which makes antibiotics the enemy. In category I they are not optional; in category II they are the treatment, given long — four weeks minimum, up to twelve, because few antibacterial agents distribute into prostatic tissue at useful concentrations (Perletti, 2013; Lam, 2023). Fluoroquinolones are first-line, with trimethoprim-sulfamethoxazole or doxycycline where the organism is susceptible, and fosfomycin against resistant organisms (Lam, 2023). Systemically unwell men start on intravenous piperacillin-tazobactam or ceftriaxone (Borgert, 2025) once they meet the admission criteria above (Coker, 2016). That same label warning applies with more force here than anywhere else on this page, because a twelve-week course is the highest-exposure scenario in the article.

What a properly negative work-up actually means

“Properly” is doing the work in that sentence. Among 488 men with category III, only 8% had at least one localising uropathogen, and neither leucocyte nor bacterial counts correlated with symptom severity (Schaeffer, 2002); factors other than leucocytes and bacteria contribute to the symptoms (Schaeffer, 2003). But a plain mid-stream urine reading “no growth” is a start, not a conclusion. It can miss bacteria sitting inside the gland, which is what the localisation tests below exist for (Lam, 2023), and it does not test for chlamydia or ureaplasma at all, which need nucleic acid amplification testing (Kaltsas, 2026). Before I tell a man he has category III I want a localisation test and a NAAT, both clean. And if a fertility work-up is also in play, semen culture and sensitivity is a separate question again — it is over-ordered, and I have written about when it is genuinely worth doing.

The plan below is what that consultation produces.

What actually treats category III

Pelvic floor physiotherapy — release, not strengthening

The evidence here is thinner than I would like. So here it is in full, rather than the flattering half.

A randomised multicentre trial recruited 48 people with either CP/CPPS or interstitial cystitis. It randomised 47 of them — 49% men, 51% women — to myofascial physical therapy or to general therapeutic massage, over up to ten weekly one-hour sessions. The response rate was 57% against 21%.

Now the caveats. Its stated purpose was to establish the feasibility of a full-scale trial, and the authors called the benefit a preliminary finding that warrants further study (FitzGerald, 2009). That is not a definitive result and I will not sell it as one. The larger Cochrane review of non-drug treatments picked acupuncture and shockwave as its clear positives, and produced no separate pelvic-floor physiotherapy estimate at all (Franco, 2018).

I recommend it anyway, for two reasons. The first is that the mechanism is coherent: the proposed sequence runs from an infectious or inflammatory initiator, through neurological injury, to pelvic floor dysfunction with increased muscle tone (Murphy, 2009). Since 1995 the condition has been framed as a psychoneuromuscular disorder driven by protective guarding and psychosocial stress (Anderson, 2018). The second is simpler — the finding is reproducible with a finger in the room.

A clenched floor does not need Kegels. In my experience Kegels teach it to clench harder, which is why I send men for release work rather than strengthening. That is my clinical position, and I will note that Murphy rates pelvic floor training and biofeedback as potentially more effective, while saying randomised trials are needed to confirm it (Murphy, 2009).

Central sensitisation — the mechanism with a name

Let me explain what’s actually happening, because this is the part that changes how a man understands his own pain. After months of pain the nervous system stops being a passive wire and starts amplifying. The AUA guideline says it plainly: we usually think of pain as a response to tissue injury that resolves with healing, but pain can also derive from neurologic origins (Lai, 2025). A clean scan and a clean culture do not mean the pain is imaginary — they mean it has moved upstream of the prostate. Hence treatments targeting neuropathic pain early rather than last in men not responding to initial measures (Rees, 2015), and pregabalin sitting in the modest-benefit column with the anti-inflammatories, at −2.4 and −2.5 to −1.7 points (Borgert, 2025). In my own practice I will also use a low-dose tricyclic or a gabapentinoid where the pain has clearly gone neuropathic — my prescribing, appearing in none of the papers cited here, and not something I would start without seeing you.

Alpha-blockers, honestly

Drugs such as tamsulosin and alfuzosin are first-line oral therapy for CP/CPPS with urinary symptoms, at −10.8 to −4.8 points against placebo (Borgert, 2025).

Against that, three findings. A meta-analysis of five placebo-controlled studies in 578 men found them ineffective as monotherapy for pain (Carona, 2025). Cochrane is uncertain about their effect on symptoms at all, on very low-quality evidence, and found raised rates of dizziness and postural hypotension (Franco, 2019). And a systematic review of six trials concluded the literature is insufficient to be certain they work — while noting that effects reached significance more often when treatment ran three months or longer (Mishra, 2007).

A 2022 network meta-analysis of 25 trials in 3,514 patients complicates it in both directions. Doxazosin came in 11.4 points below placebo (credible interval −17.5 to −5.1), past the six that matter. Yet the paper’s overall conclusion is that pharmacological treatments have little evidence supporting efficacy in CP/CPPS, and that the field should be looking for non-pharmacological targets (Qin, 2022). Hold both halves.

The rest of the toolkit. Acupuncture and extracorporeal shockwave therapy both produced clinically meaningful reductions on high-quality evidence, though the shockwave benefit may not be sustained at medium-term follow-up; prostatic massage has uncertain effects (Franco, 2018). Ibuprofen and pollen extract give modest improvements (Borgert, 2025). Heat and sitz baths cost nothing.

What ties it together: phenotyping

UPOINT sorts a man into six clinical domains — urinary, psychosocial, organ-specific, infection, neurological/systemic and muscle tenderness. Each is diagnosed clinically, and each is associated with specific therapies (Shoskes, 2013).

Note the fourth domain honestly, because it is the one someone arguing my case is tempted to skip. UPOINT keeps an infection domain. For the minority who phenotype into it — on a positive localisation culture, not a hunch — the treatment is antimicrobial. My argument has never been that no man with category-III symptoms should see an antibiotic. It is that you should be in that domain before you get one.

Across three independent studies, UPOINT-directed therapy produced significant symptom improvement in 75% to 84% of patients (Polackwich, 2016). Those are observational validation studies, as flagged above, not randomised trials. The AUA guideline runs on the same logic: multimodal and multidisciplinary, with referral to allied health professionals rather than a single drug (Lai, 2025), delivered by a team including specialist physiotherapists and psychologists (Rees, 2015).

No single item on that list is a cure. Together they are the difference between managing this and being managed by it.

No single one of these is the answer. The men who get better are the ones who get the combination matched to their particular pattern.

Is prostatitis an STD?

No — with one exception I will come to in a moment. For the great majority of men, prostatitis is not a sexually transmitted disease, it is not contagious, and you cannot give it to your partner. Look at what actually grows: 80% to 97% of acute bacterial prostatitis is caused by gram-negative organisms such as E. coli, Klebsiella or Pseudomonas, and up to 74% of chronic bacterial prostatitis by the same family (Borgert, 2025). “Up to 74%” also means a quarter or more is something else, and that is where the exception lives.

Chronic bacterial prostatitis caused by obligate intracellular pathogens behaves differently: macrolides showed higher microbiological and clinical cure rates than fluoroquinolones in that group, and in chlamydial prostatitis specifically azithromycin achieved better eradication and cure rates than ciprofloxacin. In ureaplasmal prostatitis the picture is flatter — ofloxacin versus minocycline, and azithromycin versus doxycycline, showed similar microbiological, clinical and toxicity profiles (Perletti, 2013). So chlamydia can be the trigger, and gonorrhoea is the other organism I test for — my practice, not something the cited trials measured. If chlamydia was the trigger, that organism is transmissible and your partner needs testing. After a new partner, an unprotected exposure or urethral discharge, get a NAAT test at a confidential STD clinic.

How it is actually diagnosed

Urine culture and sensitivity is the pivot

Take a culture in every man suspected of acute bacterial prostatitis (Coker, 2016). Category III is a diagnosis of exclusion, made when history, examination, urine culture and post-void residual fail to identify other causes for the symptoms, such as infection, cancer, urinary obstruction or urinary retention (Borgert, 2025). Note that cancer sits on that list — the evaluation is meant to exclude it, not assume it away. In practice the conditions I most often find instead are benign prostatic enlargement, urethritis, bladder pain syndrome, pudendal neuralgia, chronic epididymitis, an inguinal hernia or an anal fissure. That is my differential from clinic, not a list from the cited review.

The localisation tests, and the symptom score

Where there is doubt about bacteria hiding in the gland, the Meares-Stamey four-glass test or the simpler modified two-glass pre- and post-massage test can help confirm the diagnosis (Lam, 2023); localisation cultures are about 90% accurate at localising the source of recurrent infection within the lower urinary tract (Murphy, 2009). Alongside them, targeted microbiology means culture plus nucleic acid amplification testing when indicated (Kaltsas, 2026). Those two decide whether you take another antibiotic.

Expressed prostatic secretions and white cells separate IIIA from IIIB — but do not over-read the count: leucocyte and bacterial counts did not correlate with severity of symptoms (Schaeffer, 2002). Same caution for a semen report; if a line about pus cells in your semen sent you here, that needs interpreting in context. The symptom score is the NIH Chronic Prostatitis Symptom Index — thirteen items in three domains, pain, urinary symptoms and quality of life (Litwin, 2002) — scored 0 to 43, where a six-point change is considered clinically meaningful (Borgert, 2025). I score every man at the first visit and again at six weeks.

Examination, and what I do about PSA

Digital rectal examination, done gently, tells me whether the gland is tender, enlarged or boggy (Coker, 2016). It also lets me feel the pelvic floor trigger points that change the plan.

On PSA. An inflamed prostate can push the reading up. So I never act on a single raised PSA in an acutely inflamed gland — I treat the inflammation, then repeat the test six to eight weeks later once things have settled.

That repeat is not optional, and it is on you to come back for it. If the PSA is still raised on the repeat, that needs proper urological assessment, and prostatitis stops being the explanation.

Two things can be true at once here. Prostatitis is not prostate cancer, and I do not believe it turns into it — my clinical position, not something the trials cited here were designed to test. But having prostatitis does not protect you from also having cancer. “It is probably the prostatitis” is a reason to recheck the number, never a reason to stop looking. If you are over fifty, or have a family history, or the reading is high rather than borderline, get the urology opinion in parallel rather than waiting.

Red flags — when this stops being chronic and becomes an emergency

This repeats the red box at the top of the page, because it is the part that matters most. Go to an emergency department now, not in the morning, if you have fever with shaking chills, cannot pass urine at all, feel systemically unwell with severe pelvic pain, or cannot keep fluids down — those are the features that trigger admission and intravenous antibiotics (Coker, 2016). Acute urinary retention is an emergency in its own right. A prostatic abscess can also form, and its presence changes which antimicrobial is appropriate (Lam, 2023). Low blood pressure in an acute infection is the beginning of sepsis — my framing, not a word used in these papers, though low blood pressure in acute bacterial prostatitis is exactly what Murphy describes (Murphy, 2009) — and it is why “same day” is the wrong instruction here and “now” is the right one.

One safety point that appears on almost no page on the internet: the prostate must not be massaged when acute bacterial prostatitis is suspected. That is my own practice rule rather than a quoted trial — the gland is acutely infected, and vigorous massage risks pushing organisms into the bloodstream.

Can prostatitis be cured?

Category I is curable. Oral ciprofloxacin has a 92% to 97% success rate when prescribed for two to four weeks in febrile urinary infection with acute prostatitis (Borgert, 2025).

Category II is usually controllable, but be realistic about relapse. Cure is attempted with long-term antibacterial therapy and relapses are frequent (Perletti, 2013); recurrence after oral antimicrobial therapy is common, partly from rising resistance and partly because the bacteria are never fully cleared from the gland (Su, 2020). Expect four to twelve weeks of treatment (Lam, 2023).

Category III is controlled rather than cured — and controlled well. It is a heterogeneous syndrome with no one-size-fits-all therapy backed by level-one evidence, and the nihilistic approach that follows is what leaves men untreated with poor outcomes (Polackwich, 2016). But 75% to 84% improve significantly with phenotype-directed therapy across three independent studies (Polackwich, 2016), and a meta-analysis of eight studies in 280 men found a weighted mean fall of 8.8 points from baseline on the symptom index when the condition was treated as a psychoneuromuscular disorder, over courses of eight to twenty-six weeks averaging fourteen — past the six points that count, and, as I said above, a before-and-after figure with no placebo arm (Anderson, 2018). Men with CP/CPPS do have a dismal quality of life and many have benefited only minimally from empirical therapy (Schaeffer, 2003): an argument for better treatment, not resignation.

The timeline you should expect

Days to weeks for category I; weeks to months for category II; for category III, plan in months — three to six of consistent, phenotype-directed work. A flare in category III is not failure and not evidence an infection is back, because there was no infection to come back. Category II is different: if you had a documented organism and your symptoms return, assume it may have relapsed and get re-cultured, because recurrence after oral antimicrobial treatment is common (Su, 2020).

Sex, ejaculation and fertility

Sexual dysfunction is present in 62% of men with CP/CPPS: erectile dysfunction in 29% and premature ejaculation in 40% (Li, 2016). Painful ejaculation is a core symptom (Murphy, 2009), and pain arriving with orgasm teaches a man to rush or brace — which is how premature ejaculation gets built on top of pelvic pain. The link runs both ways: in a small study of 46 men presenting with PE against 30 controls, prostatic inflammation was found in 56.5% and chronic bacterial prostatitis in 47.8%, significantly more than in controls, and the authors stressed careful examination of the prostate before any drug or psychosexual therapy (Screponi, 2001). Yet most men with PE in India are handed dapoxetine by a chemist without anyone examining the gland. Erectile difficulty alongside pelvic pain is common enough that I now ask directly.

What it does to fertility

Prostatitis can genuinely affect semen quality. Studies have demonstrated a reduction in semen parameters in CP/CPPS, and several mechanisms have been proposed to link the two, including male accessory gland inflammation (Graziani, 2023). Across prostatitis categories, leucocytes in semen and raised seminal cytokines are associated with impaired motility, altered viscosity and liquefaction, oxidative stress and higher sperm DNA fragmentation (Kaltsas, 2026). In the silent category IV, raised seminal interleukin-6 correlates closely with the semen white cell count (Korrovits, 2006). These are treatable drivers, found by evaluation beyond a routine semen analysis (Kaltsas, 2026). CP/CPPS is not permanent infertility.

Living with it day to day

Stand up every forty minutes at a desk, and offload the perineum with a cushion if riding is unavoidable. During a flare cut alcohol, caffeine, chilli and acidic food, then reintroduce them one at a time — most men have one or two personal triggers, not a universal list.

Drink enough water, treat urinary infections early, and keep moving: a structured physical activity programme may produce a small reduction in symptoms (Franco, 2018). Treat stress as part of the plan, because behavioural therapy sits inside the guideline (Lai, 2025). None of this replaces the plan above — it is what makes the plan hold between appointments.

Still unsure?

Get the two tests that were skipped

A localisation culture and a NAAT, a proper pelvic floor examination, and a symptom score so progress is measurable rather than a matter of opinion.

Book a Consultationor call +91 97907 83856

Frequently asked questions

What happens if I ignore prostatitis?

Which category you are in decides the answer completely. Ignore category III and nothing catastrophic happens to the gland, but the symptoms persist and quality of life falls — men with CP/CPPS have a dismal quality of life on the published data (Schaeffer, 2003). Ignore category I and you are taking a real risk: it is an acute infection that can come with fever, chills and low blood pressure (Murphy, 2009), a prostatic abscess can form (Lam, 2023), and men who are systemically ill, cannot urinate or cannot keep fluids down need hospital admission and intravenous antibiotics (Coker, 2016). Ignore category II and the infection tends to keep recurring (Su, 2020).

How to cure prostatitis quickly?

Only category I. Oral ciprofloxacin has a 92% to 97% success rate over two to four weeks in febrile urinary infection with acute prostatitis (Borgert, 2025). Category III has no fast route.

How to flush out prostatitis?

You cannot. In the great majority of category III cases nothing is lodged in the gland — 92% of the men in the NIH category III cohort had no localising organism (Schaeffer, 2002). Herbal cleanses do not drain the prostate.

Can prostatitis be cured?

Category I, yes — a two-to-four week course clears it (Borgert, 2025). For category II, usually, but be realistic: it takes four to twelve weeks (Lam, 2023), relapses are frequent (Perletti, 2013) and recurrence after oral therapy is common (Su, 2020). The third category is controlled rather than cured, and 75% to 84% improve significantly with phenotype-directed treatment (Polackwich, 2016).

Which antibiotic is the best for prostatitis?

For bacterial prostatitis, fluoroquinolones first, then trimethoprim-sulfamethoxazole or doxycycline if susceptible, fosfomycin if resistant (Lam, 2023); different fluoroquinolones perform comparably (Perletti, 2013). For category III there is no “best” — that is the argument on this page. Placebo-controlled trials were negative (Alexander, 2004; Nickel, 2003) while guidelines still list antibiotics among first-line options (Rees, 2015).

How to treat prostatitis without antibiotics?

The right question for most men with category III: pelvic floor physiotherapy aimed at release (FitzGerald, 2009), alpha-blockers for urinary symptoms (Borgert, 2025), treatments targeting neuropathic pain (Rees, 2015), acupuncture or shockwave therapy (Franco, 2018), and phenotype-directed multimodal care rather than one drug (Polackwich, 2016).

Can you get prostatitis without an STD?

Yes — that is the normal situation. Most bacterial cases are caused by gram-negative organisms rather than sexually transmitted ones (Borgert, 2025), and in the commonest category only 8% of men have any localising organism at all (Schaeffer, 2002).

Can a woman catch prostatitis from a man?

No. It is inflammation of a gland only men have, and it does not transmit. If chlamydia triggered yours (Perletti, 2013), that organism is transmissible and your partner should be tested — at a confidential STD clinic, together, rather than one of you at a time.

Does ejaculating help clear prostatitis?

Nobody has tested this properly. The nearest evidence is on prostatic massage, a different thing done by a clinician — and even there we are uncertain whether it reduces or increases symptoms (Franco, 2018). In clinic I tell men to be guided by whether it hurts; my advice, not a trial result.

Can prostatitis be caused by not ejaculating?

No. The aetiology of category III is poorly understood, but the proposed sequence is an infectious or inflammatory initiator producing neurological injury and ending in pelvic floor dysfunction with increased muscle tone (Murphy, 2009) — not an unemptied gland.

What is a red flag for pelvic pain?

Fever with rigors, inability to pass urine, feeling systemically unwell, or being unable to keep fluids down — any of those means an emergency department now, not a morning appointment. They are the same features that trigger admission and intravenous antibiotics (Coker, 2016).

You are not making it up, and you are not stuck with it

If you have had three courses of antibiotics with clean cultures each time, you have not failed treatment. You have probably been given the wrong treatment for the category you are in — and the way to find out is to do the two tests that were skipped, not to take a fourth course.

Get the localisation test and the NAAT done properly once. Get the pelvic floor examined by someone who knows what they are feeling for. Get a symptom score at the start, so improvement is measurable rather than a matter of opinion. And give it months rather than days.

If that is where you are, come and have it looked at properly — bring the folder of old reports. Most men leave with fewer prescriptions than they expected and a plan that matches what they actually have.

References

1. Alexander (2004). Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Annals of Internal Medicine. PMID 15492337
2. Anderson (2018). Chronic Prostatitis and/or Chronic Pelvic Pain as a Psychoneuromuscular Disorder — A Meta-analysis. Urology. PMID 30056195
3. Anothaisintawee (2011). Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. PMID 21205969
4. Borgert (2025). Prostatitis: A Review. JAMA. PMID 40788632
5. Carona (2025). A systematic review and meta-analysis of alpha-adrenergic antagonists for the treatment of pain in chronic prostatitis. World Journal of Urology. PMID 40169407
6. Coker (2016). Acute Bacterial Prostatitis: Diagnosis and Management. American Family Physician. PMID 26926407
7. FitzGerald (2009). Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. The Journal of Urology. PMID 19535099
8. Franco (2018). Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews. PMID 29757454
9. Franco (2019). Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews. PMID 31587256
10. Graziani (2023). Chronic Prostatitis/Chronic Pain Pelvic Syndrome and Male Infertility. Life (Basel). PMID 37629557
11. Kaltsas (2026). Prostatitis-Related Male Infertility: From Inflammation and Dysbiosis to Sperm DNA Damage. Diagnostics (Basel). PMID 41827997
12. Korrovits (2006). Seminal microflora in asymptomatic inflammatory (NIH IV category) prostatitis. European Urology. PMID 16762488
13. Krieger (1999). NIH consensus definition and classification of prostatitis. JAMA — Letter; cited here at title level only. PMID 10422990
14. Lai (2025). Male Chronic Pelvic Pain: AUA Guideline, Part II — Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. The Journal of Urology. PMID 40243102
15. Lam (2023). How I manage bacterial prostatitis. Clinical Microbiology and Infection. PMID 35709903
16. Li (2016). Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. World Journal of Urology. PMID 26546073
17. Litwin (2002). A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology. PMID 12521581
18. Mishra (2007). Role of alpha-blockers in type III prostatitis: a systematic review of the literature. The Journal of Urology. PMID 17161995
19. Murphy (2009). Chronic prostatitis: management strategies. Drugs. PMID 19192937
20. Nickel (2003). Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology. PMID 14550427
21. Perletti (2013). Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database of Systematic Reviews. PMID 23934982
22. Polackwich (2016). Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer and Prostatic Diseases. PMID 26951713
23. Qin (2022). Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis of randomised controlled trials. EClinicalMedicine. PMID 35706494
24. Rees (2015). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU International. PMID 25711488
25. Roberts (2000). Epidemiology of prostatitis. Current Urology Reports. PMID 12084327
26. Schaeffer (2002). Classification (traditional and National Institutes of Health) and demographics of prostatitis. Urology. PMID 12521577
27. Schaeffer (2003). Epidemiology and demographics of prostatitis. Andrologia. PMID 14535850
28. Screponi (2001). Prevalence of chronic prostatitis in men with premature ejaculation. Urology. PMID 11489699
29. Shoskes (2013). Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World Journal of Urology. PMID 23588814
30. Su (2020). Management of Chronic Bacterial Prostatitis. Current Urology Reports. PMID 32488742